https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-12 13:08:582023-09-12 13:08:58IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-09-12 13:08:582023-09-12 13:08:58IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer
Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer
Ariceum develops satoreotide its first and best-in-class somatostatin…

IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Vicore Pharma Announces Presentations at the European Respiratory Society (ERS) International Congress 2023
Stockholm, September 6, 2023 – Vicore Pharma Holding AB…

Alchemab Therapeutics CEO to Present at Wells Fargo 2023 Healthcare Conference
Cambridge, UK, September 5, 2023 – Alchemab Therapeutics, an…

Six companies enter BioInnovation Institute’s Venture House program receiving additional financial support
BioInnovation Institute (BII), an international non-profit foundation…

Astraveus Appoints Microfluidic expert Etienne Fradet as Chief Technical Officer
• Etienne Fradet brings extensive industry expertise and a…

Lytix Biopharma presents first half and second quarter 2023 results
OSLO, Norway, August 31 2023. Lytix Biopharma – Lytix Biopharma…

The BioInnovation Institute welcomes eight new companies to its Venture Lab program
COPENHAGEN, Denmark, August 31, 2023 – BioInnovation Institute…

Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at European Society of Cardiology Congress 2023
Evidence that 13-M, a unique small molecule disruptor of adrenergic…

Lytix Biopharma announces completion of patient recruitment in the ATLAS-IT-05 trial
Oslo, 29 August 2023. Lytix Biopharma – Lytix Biopharma AS…

Vicore Pharma: Interim Report April-June 2023
Stockholm, August 24, 2023 - Vicore Pharma Holding AB (STO: VICO)…

Vicore reports data from EndoPAT® exploratory trial
Stockholm, August 22, 2023 – Vicore Pharma Holding AB (STO:…

Interim Report Q2, 2023
Filing for full approval of TARPEYO
FINANCIAL SUMMARY FOR…

Novo Holdings participates in $290m strategic financing of Sangon Biotech
Novo Holdings, a leading international life science investor,…

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

IO Biotech Announces 2023 Second Quarter Results
Achieved significant enrollment milestone in pivotal Phase…

IO Biotech Appoints Heidi Hunter to its Board of Directors
NEW YORK, Aug. 11, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq:…

Lytix Biopharma’s licensing partner Verrica Pharmaceuticals Inc. reports interim Phase II data with LTX-315
Promising clinical results showed clearance of basal cell carcinoma…

4SC provides Q2 2023 and H1 2023 update
Positive topline data for resminostat in RESMAIN pivotal…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York